Tempest posts early PFS, OS data on liver cancer combo, eyes pivotal trial for TPST-1120news2023-10-11T12:00:37+00:00October 11th, 2023|Endpoints News|
Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic testnews2023-10-11T12:00:20+00:00October 11th, 2023|Endpoints News|
Novo Nordisk to close PhIIIb trial of semaglutide in kidney disease ‘for efficacy’news2023-10-11T11:15:14+00:00October 11th, 2023|Endpoints News|
MinervaX raises €54M in upsized financing round to progress group B Streptococcus vaccinenews2023-10-11T07:00:42+00:00October 11th, 2023|Endpoints News|
Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C roundsnews2023-10-11T05:00:43+00:00October 11th, 2023|Endpoints News|
Sana narrows focus to ex vivo cell therapies, lays off 29% of staff to reach key clinical datanews2023-10-10T20:15:57+00:00October 10th, 2023|Endpoints News|
Almost a year since Humira biosimilars launched, AbbVie still controls more than 97% of the US marketnews2023-10-10T19:44:49+00:00October 10th, 2023|Endpoints News|
Employers covering GLP-1s could double in 2024 as questions over coverage guardrails loomnews2023-10-10T19:07:50+00:00October 10th, 2023|Endpoints News|
Pfizer cuts jobs at Boulder, CO, research facilitynews2023-10-10T18:45:37+00:00October 10th, 2023|Endpoints News|
FDA warns two websites selling Novo, Lilly blockbuster weight loss drugsnews2023-10-10T18:30:33+00:00October 10th, 2023|Endpoints News|
